Find latest Prostate Cancer videos
·
100+ videos
Precision Oncology in Practice: Testing to Treatment in Lung and Prostate Cancer
By
COR2ED The Heart of Medical Education
FEATURING
Fernando López-Ríos
By
COR2ED The Heart of Medical Education
FEATURING
Fernando López-Ríos
In a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Assoc. Prof. Alicia Morgans and Assoc. Prof. Herbert Loong came together to explore precision oncology in practice for lung and prostate cancer.
Watch the on-demand video to hear the medical experts discuss how to address pre-analytical phase challenges during molecular testing, and the relevant biomarkers and tests to request for lung and prostate cancer patients.
Key clinical takeaways:
- Molecular testing with next-generation sequencing of DNA and RNA should be considered standard of care where possible using high-quality, sufficient tissue samples for accurate biomarker testing
- Pathologists should conduct ‘reflex testing’ after histologic diagnosis of lung cancer, and liquid biopsies should be utilised as a complementary testing method or when tumour tissue is not feasible
- Germline and somatic genetic testing in advanced prostate cancer may identify patients with HRR mutations and MSI-H who could be suitable for highly effective targeted agents
Multidisciplinary team or molecular tumour board discussion can facilitate interpretation of biomarker data, leading to more accurate patient stratification, treatment selection, and clinical decision-making
Watch the video replay and download the accompanying slides by visiting the COR2ED website
April 2024
Watch the on-demand video to hear the medical experts discuss how to address pre-analytical phase challenges during molecular testing, and the relevant biomarkers and tests to request for lung and prostate cancer patients.
Key clinical takeaways:
- Molecular testing with next-generation sequencing of DNA and RNA should be considered standard of care where possible using high-quality, sufficient tissue samples for accurate biomarker testing
- Pathologists should conduct ‘reflex testing’ after histologic diagnosis of lung cancer, and liquid biopsies should be utilised as a complementary testing method or when tumour tissue is not feasible
- Germline and somatic genetic testing in advanced prostate cancer may identify patients with HRR mutations and MSI-H who could be suitable for highly effective targeted agents
Multidisciplinary team or molecular tumour board discussion can facilitate interpretation of biomarker data, leading to more accurate patient stratification, treatment selection, and clinical decision-making
Watch the video replay and download the accompanying slides by visiting the COR2ED website
April 2024
Comments 0
Login to view comments.
Click here to Login
